Ovid Therapeutics (OVID) Shares Outstanding (2016 - 2026)

Ovid Therapeutics (OVID) has reported Shares Outstanding (Entity) for 11 consecutive years, with $184.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 159.82% year-over-year to $184.8 million; the trailing twelve-month figure through Jun 2026 stood at $184.8 million (up 159.82% YoY), and the FY2025 full-year result was $73.7 million, up 3.84% from the prior year.
• Shares Outstanding (Entity) improved to $184.8 million in Q2 2026 per OVID's latest filing, from $136.2 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $184.8 million in Q2 2026 and bottomed at $70.4 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $80.9 million across 5 years, with a median of $70.9 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Entity) climbed 0.11% in 2023, then surged 159.82% in 2026.
• Over 5 years, Shares Outstanding (Entity) stood at $70.5 million in 2022, then advanced by 0.32% to $70.7 million in 2023, then increased by 0.45% to $71.0 million in 2024, then rose by 3.84% to $73.7 million in 2025, then jumped by 150.56% to $184.8 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $184.8 million, $136.2 million, and $73.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.